Adagio Medical Provides Business Update: 22 Patients Treated with Next-Generation vCLAS™ Ultra System as FULCRUM-VT IDE Sub-Study Advances

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today provided a business update highlighting continued execution of its FULCRUM-VT IDE study and FULCRUM-VT IDE sub-study, as well as progress of its previously announced review of strategic alternatives. Clinical Update To date, the Company has treated a total of 22 patients with the Com